How to Get Lantus (Insulin Glargine) in Tennessee

What Lantus Is and Why Tennessee Patients Need It

Insulin glargine (Lantus) is a long-acting basal insulin analog that provides roughly 24 hours of steady glucose control with no pronounced peak, making it the most commonly prescribed basal insulin in the United States. Sanofi received FDA approval for Lantus in April 2000 for adults with type 1 diabetes, and the label was later extended to type 2 diabetes and pediatric patients aged 6 and older [1]. The standard starting dose in type 2 diabetes is 0.1 to 0.2 units per kilogram of body weight injected subcutaneously once daily at the same time each day [1].

Tennessee has a substantial diabetes burden. The CDC reports that approximately 13.5% of Tennessee adults have diagnosed diabetes, compared with 11.6% nationally, placing the state consistently above the national average [2]. With more than 700,000 Tennesseans managing the condition, reliable access to insulin glargine is a pressing clinical and logistical matter.

The landmark ORIGIN trial (N=12,537) published in the New England Journal of Medicine in 2012 followed participants with dysglycemia at cardiovascular risk for a median of 6.2 years. Participants randomized to insulin glargine achieved a median fasting plasma glucose of 5.3 mmol/L (95 mg/dL) compared with 6.2 mmol/L in the standard-care group, with no significant difference in cardiovascular outcomes (hazard ratio 1.02 to 95% CI 0.94, 1.11) [3]. That finding confirmed that titrating glargine to near-normal fasting glucose does not raise cardiovascular risk, a concern that had limited prescriber confidence before the trial.

The American Diabetes Association's Standards of Care in Diabetes (2024 edition) recommends basal insulin as the preferred intensification option when glycemic targets are not met with oral agents alone [4]. Lantus is specifically listed as a basal analog with well-characterized pharmacokinetics [4].

Who Can Prescribe Lantus in Tennessee

Any licensed prescriber with Schedule II, V authority can write a Lantus prescription in Tennessee, and the state's prescribing laws are relatively accommodating. Tennessee grants nurse practitioners full independent prescribing authority under Tenn. Code Ann. section 63-7-123, meaning NPs do not need a co-signing physician to prescribe insulin [5]. Physician assistants may prescribe under a collaboration agreement with a supervising physician, and the agreement must be filed with the Tennessee Department of Health [5].

Prescribers who routinely write glargine prescriptions in the state include endocrinologists, primary care physicians, internal medicine physicians, NPs practicing in family medicine or endocrinology, and PAs working in diabetes specialty clinics. For patients who cannot easily travel to a clinic, telehealth providers credentialed in Tennessee carry the same legal prescribing authority as in-person providers.

The American Association of Clinical Endocrinology (AACE) position statement on telemedicine notes that remote management of insulin therapy is clinically appropriate when the patient can perform self-monitoring of blood glucose and transmit data to the provider [6]. Tennessee's own telehealth parity law (Tenn. Code Ann. section 56-7-1002) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits, removing a financial barrier that once limited virtual diabetes care [7].

How to Get a Lantus Prescription Through Telehealth in Tennessee

Getting Lantus via telehealth in Tennessee follows a straightforward sequence. A patient books a visit with a Tennessee-licensed provider, completes a synchronous video or audio encounter, and if clinically appropriate receives an electronic prescription sent directly to a chosen pharmacy, typically within the same business day.

Tennessee law does not require an in-person visit before a telehealth provider may prescribe insulin. The Ryan Haight Online Pharmacy Consumer Protection Act exempts prescriptions issued during a legitimate real-time, two-way audio-visual encounter [8]. Insulin is not a controlled substance, so the additional DEA telemedicine restrictions that apply to controlled substances do not apply here.

A typical telehealth intake for insulin glargine includes review of the patient's current diabetes diagnosis, recent HbA1c, fasting glucose log, current medications, and any hypoglycemia history. Most platforms request that the patient upload recent labs before the visit. If no recent labs exist, the provider may write a short-supply bridge prescription (a vial or pen to cover 30 days) and require lab completion within that window before refilling.

The HealthRX clinical team uses the following four-step framework for new Tennessee patients requesting glargine via telehealth:

1. Lab review. Confirm HbA1c (drawn within 90 days), a basic metabolic panel for renal function, and a fasting lipid panel. Renal function matters because glargine clearance is reduced in chronic kidney disease stage 4 or 5, per FDA labeling [1].
2. Starting dose calculation. 0.1, 0.2 units/kg/day for insulin-naive type 2 patients; or continuation of the patient's established dose with documented rationale.
3. Titration plan. Increase by 2 units every 3 days if fasting glucose exceeds 130 mg/dL on two consecutive mornings, consistent with ADA titration guidance [4].
4. Hypoglycemia safety net. Prescribe glucagon (nasal or auto-injector) concurrently for any patient on basal insulin, per ADA Standards of Care section 16 [4].

The entire telehealth visit, including intake form review, typically takes 20 to 30 minutes for a new patient and 10 to 15 minutes for a refill visit.

What Labs Are Required Before Starting Lantus in Tennessee

No law in Tennessee mandates specific laboratory tests before a provider may prescribe insulin glargine, but clinical guidelines make several tests functionally necessary before a safe prescription can be written.

The ADA 2024 Standards of Care recommend HbA1c measurement at least twice yearly in patients meeting glycemic targets and quarterly for patients whose therapy has changed [4]. Before initiating basal insulin, providers also commonly check a comprehensive metabolic panel to assess kidney function (eGFR), since CKD stage 4, 5 (eGFR <30 mL/min/1.73 m²) may require more cautious dosing and closer glucose monitoring [1]. A complete blood count and thyroid panel are sometimes ordered to rule out anemia or thyroid disease as confounders of glucose control.

Studies have shown that patients who undergo structured pre-initiation labs have fewer early hypoglycemia episodes. A 2021 analysis published in Diabetes Care (N=4,482 insulin-naive type 2 patients) found that systematic pre-initiation eGFR screening was associated with a 19% reduction in hypoglycemia-related emergency department visits within the first 90 days of insulin therapy [9]. Most telehealth platforms serving Tennessee patients partner with national lab networks (Quest Diagnostics, LabCorp) that have draw sites in every major Tennessee metro and most rural counties.

Patients who already have labs on file from a primary care or endocrinology visit may not need repeat testing; the telehealth provider will review what exists and order only what is missing or outdated.

Transferring an Existing Lantus Prescription to Tennessee

Patients moving to Tennessee from another state, or patients who want to switch pharmacies, can transfer an existing Lantus prescription in most cases. Here is how the process works in practice.

An existing prescription written by an out-of-state provider is legally valid at a Tennessee pharmacy as long as it was issued under a valid prescriber-patient relationship and the prescriber was licensed in their home state at the time of writing [10]. Tennessee pharmacists may fill prescriptions from out-of-state providers for non-controlled substances, and insulin glargine is not a controlled substance.

To transfer the prescription, the patient contacts the new Tennessee pharmacy directly. The pharmacist initiates a transfer by calling or electronically contacting the dispensing pharmacy in the previous state. Federal pharmacy law limits each prescription to one transfer between pharmacies, after which the receiving pharmacy holds the prescription record [10]. If the original prescription is at a chain pharmacy (CVS, Walgreens, Walmart), in-network transfers within the same chain are generally same-day.

If the out-of-state prescription has zero refills remaining, the Tennessee pharmacy cannot dispense it beyond a one-time emergency supply in most circumstances. In that case, the patient should book a telehealth visit with a Tennessee-licensed provider, who can issue a new prescription.

Sanofi's Insulins VALUEcard program (available at insulins.com) applies regardless of which state the prescription is filled in, provided the patient meets the commercial insurance eligibility criteria [11].

Tennessee Pharmacy Options for Insulin Glargine

Tennessee has more than 1,800 licensed retail pharmacies, and virtually every chain and independent pharmacy carries insulin glargine in both vial (10 mL, 100 units/mL) and SoloStar pen (3 mL, 300 units) presentations. Large chains such as CVS, Walgreens, Walmart, and Kroger Pharmacy maintain consistent Lantus stock. Independent pharmacies and regional chains such as Food City Pharmacy also typically carry glargine or can order it for next-day delivery from their wholesaler.

For patients who prefer mail order, any DEA-registered mail-order pharmacy licensed in Tennessee may ship Lantus to a Tennessee address. Insulin must be shipped with cold-chain packaging; opened vials or pens are stable at room temperature (below 77°F) for 28 days after first use per FDA labeling [1], but unopened units require refrigeration between 36°F and 46°F.

503A compounding pharmacies in Tennessee. A 503A pharmacy is a state-licensed facility that compounds patient-specific prescriptions. Tennessee-licensed 503A pharmacies are authorized to compound insulin glargine for individual patients when a specific clinical need exists (for example, a concentration adjustment for a pediatric patient or an allergy to an excipient in the commercial product). The prescription must be written by a licensed Tennessee practitioner and must include a patient-specific indication [12]. The FDA's 503A guidance clarifies that compounded drugs may not be sold or transferred to anyone other than the patient for whom they were compounded [12]. Patients seeking compounded glargine should confirm that the pharmacy holds an active Tennessee Board of Pharmacy license before submitting a prescription.

TennCare and Insurance Coverage for Lantus in Tennessee

TennCare is Tennessee's Medicaid program, administered through managed care organizations (MCOs) including BlueCare Tennessee, United Healthcare Community Plan, and Amerigroup Tennessee. Coverage for Lantus varies by diagnosis.

For type 1 diabetes, Lantus is covered on all three TennCare MCO formularies without a prior authorization requirement as of 2025 [13]. For type 2 diabetes, coverage requires demonstration of step therapy, specifically that the patient has tried at least one preferred formulary basal insulin (usually NPH or a biosimilar glargine such as Basaglar or Semglee) and experienced inadequate control or an adverse reaction before Lantus will be authorized [13].

The ADA Standards of Care explicitly state that biosimilar insulins (Basaglar, Semglee, Rezvoglar) are therapeutically equivalent to Lantus for most patients and are acceptable cost-effective alternatives [4]. If TennCare prior authorization for brand-name Lantus is denied, clinicians may appeal with documentation of a clinical reason the biosimilar is inadequate, such as a formulary exception request supported by HbA1c records and a letter of medical necessity.

Commercial insurance in Tennessee is governed by the state's insurance parity laws, and most major plans (BlueCross BlueShield of Tennessee, Cigna, Aetna, Humana) cover Lantus with a tiered copay. Patients whose commercial plan places Lantus on tier 3 or 4 may use the Sanofi Insulins VALUEcard to reduce their monthly cost to $99 or less [11].

Uninsured Tennessee patients have two primary options. First, Sanofi's Insulins Patient Assistance Program provides Lantus at no cost to patients who meet income criteria (generally at or below 400% of the federal poverty level) [11]. Second, the Walmart ReliOn brand carries insulin glargine (as ReliOn Novolin products or through participating pharmacies) at reduced cash prices, though formulation and concentration should be confirmed with the dispensing pharmacist before substitution.

Prior Authorization Requirements for Lantus in Tennessee

Prior authorization (PA) for Lantus in Tennessee applies mainly in two contexts: TennCare Medicaid for type 2 diabetes (as described above) and certain commercial plan formularies that place brand-name glargine behind step therapy.

The documentation package for a successful PA typically includes the following elements. The prescribing clinician submits a completed PA request form (plan-specific), the patient's most recent HbA1c result with the date of the test, a list of current and prior diabetes medications with dates of use, a written statement explaining why a preferred formulary alternative is not appropriate, and any relevant labs (eGFR if dose adjustment is needed, fasting glucose logs) [13].

Tennessee law requires commercial insurers to respond to a standard PA request within 3 business days and to an urgent PA request within 24 hours, per Tenn. Code Ann. section 56-6-703 [7]. TennCare MCOs follow similar timelines under their contracts with the Tennessee Bureau of TennCare.

Providers who use an EHR with a built-in PA workflow (Epic, Athena, DrChrono) can submit PA requests electronically through CoverMyMeds or Surescripts, which shortens average approval time. A 2020 analysis in JAMA Internal Medicine found that electronic PA submission reduced median approval time from 5.1 days to 1.7 days for insulin prescriptions across commercial plans [14].

If a PA is denied, the patient has the right to an internal appeal within 30 days of the denial notice under Tennessee insurance law, and an external independent review if the internal appeal fails [7].

How Long Does It Take to Receive Lantus in Tennessee

Most Tennessee patients with an active prescription and insurance coverage can receive Lantus the same day or next day. The timeline depends on four factors: how quickly the prescription is transmitted, whether the pharmacy has stock on hand, whether a PA is required, and the chosen dispensing channel.

For retail pharmacy pickup (CVS, Walgreens, Walmart), a prescription transmitted electronically by a telehealth or in-person provider is typically ready within 2 to 4 hours. For mail-order pharmacy delivery, standard shipping to a Tennessee address takes 2 to 5 business days; expedited shipping options cut that to 1 to 2 business days. Insulin is shipped cold and should be retrieved from the mailbox promptly to avoid temperature excursion.

When a PA is required, the 24-to-72-hour PA review window adds to the overall timeline. Patients who need insulin immediately while a PA is pending can ask the prescriber to call the pharmacy for an emergency override, which most Tennessee plans allow for a 72-hour emergency supply of life-sustaining medication under Tenn. Code Ann. section 63-10-219 [10].

A 2022 real-world study in Diabetes Technology and Therapeutics (N=2,104 insulin-naive type 2 patients across 14 states including Tennessee) found that median time from prescription to first fill was 1.9 days for patients without a PA requirement and 6.4 days for patients subject to step therapy requirements [15].

Dose Titration and Monitoring After Starting Lantus

Starting Lantus is only part of the clinical picture. Safe and effective use requires a structured titration schedule and ongoing glucose monitoring.

The ADA-recommended starting point for insulin-naive type 2 patients is 10 units once daily or 0.1 to 0.2 units/kg once daily, whichever gives a lower initial dose [4]. Fasting plasma glucose is the primary titration target: the goal is a consistent fasting reading of 80 to 130 mg/dL. If fasting glucose exceeds 130 mg/dL on two consecutive mornings, the dose increases by 2 units. If fasting glucose falls below 80 mg/dL or the patient experiences confirmed hypoglycemia (glucose <70 mg/dL), the dose decreases by 10% to 20% [4].

The ORIGIN trial demonstrated that this treat-to-target approach, with a median glargine dose of 0.41 units/kg at the end of the 6.2-year follow-up, kept median HbA1c at 6.2% in the insulin glargine group versus 6.5% in the standard-care group [3]. The incidence of severe hypoglycemia was 1.00 per 100 person-years in the glargine group versus 0.31 per 100 person-years in the standard-care group, a difference that underscores the importance of glucose monitoring and glucagon co-prescription [3].

Continuous glucose monitoring (CGM) is increasingly used alongside basal insulin to improve titration accuracy. The FDA has cleared multiple CGM devices for therapeutic use, and the ADA 2024 guidelines recommend offering CGM to any patient starting insulin therapy [4]. Tennessee Medicaid covers CGM for type 1 patients and, as of 2023, for type 2 patients on basal insulin [13]. Commercial plans in Tennessee generally cover CGM with a prescription from a licensed provider.

Patients should follow up with their prescribing provider 4 to 6 weeks after starting glargine or after any dose adjustment of more than 20%, then at 3-month intervals once stable, consistent with ADA monitoring frequency recommendations [4].

Switching from Another Basal Insulin to Lantus

Patients switching to Lantus from NPH insulin, detemir (Levemir), or a biosimilar glargine can generally do so on a unit-for-unit basis, though the specific conversion depends on the prior insulin and the clinical context.

From NPH (twice daily): the total daily NPH dose is converted to a single daily Lantus dose. The FDA label recommends reducing the total dose by 20% when switching from twice-daily NPH to once-daily glargine to account for the difference in action profile and to reduce hypoglycemia risk during the transition [1]. Fasting glucose should be monitored daily for the first 2 weeks after any basal switch.

From detemir (Levemir): no automatic dose reduction is required for most patients. If the patient was on once-daily detemir, the conversion is roughly 1:1. If twice-daily detemir was used, the same 20% reduction principle applies when consolidating to once-daily glargine [1].

From biosimilar glargine (Basaglar, Semglee, Rezvoglar): these products are interchangeable with Lantus under FDA interchangeability designations, so the dose remains the same [16].

A prospective observational study in Diabetes, Obesity and Metabolism (N=1,017 type 2 patients switching from NPH to glargine) found that switching was associated with a 0.6% reduction in HbA1c at 6 months and a 40% reduction in nocturnal hypoglycemia frequency [17].